[13C6]-Nafamostat mesylate

[13C6]-Nafamostat mesylate is a stable isotope-labeled form of Nafamostat mesylate, a synthetic serine protease inhibitor that is commonly used in the treatment of pancreatitis, disseminated intravascular coagulation, and COVID-19. It is a white to off-white powder that is soluble in water and has a molecular weight of 495.6 g/mol. This stable isotope-labeled form of Nafamostat mesylate is used in metabolic studies to determine the pharmacokinetics and pharmacodynamics of the drug. It is also used in drug-drug interaction studies, where it is co-administered with other drugs to investigate their effects on Nafamostat mesylate metabolism and clearance. This information is important in drug development and clinical trials to ensure the safety and efficacy of the drug. Chemically, [13C6]-Nafamostat mesylate is labeled with six carbon-13 atoms, which are stable isotopes of carbon. These isotopes have the same chemical properties as the more common carbon-12, but differ in their atomic mass. This labeling allows for the drug to be easily distinguished from the unlabeled form in metabolic studies. In summary, [13C6]-Nafamostat mesylate is an important tool in drug development and clinical trials, allowing for the determination of the pharmacokinetics and pharmacodynamics of Nafamostat mesylate and its interactions with other drugs. Its stable isotope labeling provides a reliable method for tracking the drug in metabolic studies.